Aquaporin-4 IgG neuromyelitis optica spectrum disorder onset after Covid-19 vaccination: Systematic review.
- Resource Type
- Case Study
- Authors
- Harahsheh, Ehab; Callister, Marcus; Hasan, Shemonti; Gritsch, David; Valencia-Sanchez, Cristina
- Source
- Journal of Neuroimmunology. Dec2022, Vol. 373, pN.PAG-N.PAG. 1p.
- Subject
- *NEUROMYELITIS optica
*COVID-19 vaccines
*AQUAPORINS
*CENTRAL nervous system diseases
*COVID-19
*TRANSVERSE myelitis
- Language
- ISSN
- 0165-5728
Neuromyelitis optica spectrum disorder (NMOSD) is rarely reported following Coronavirus disease 2019 (COVID-19) vaccination. We identified 16 cases of new onset NMOSD with positive aquaporin-4 IgG (AQP4-IgG) following COVID-19 vaccination. Transverse myelitis was the most common clinical presentation (75%). Most patients received high dose steroids for acute treatment and maintenance therapy was started in 12 patients (75%). Twelve patients (75%) had improvement of their symptoms at the time of discharge or follow-up. The included cases share similar epidemiology and natural course to non-vaccine related cases. Clinicians should be aware of possible post-vaccination NMOSD to help with earlier diagnosis and treatment. • NMOSD is an inflammatory demyelinating disease of the central nervous system. • COVID-19 infection and vaccination have been associated with development of NMOSD. • New onset NMOSD developing following COVID-19 vaccines share similar epidemiology to non-vaccine related cases. [ABSTRACT FROM AUTHOR]